Cargando…

PB2104: DOSE-DENSE CHEMOTHERAPY WITH R-CHOP-14 IN OLDER ADULTS AGED ≥80 YEARS WITH DIFFUSE LARGE B-CELL LYMPHOMA

Detalles Bibliográficos
Autores principales:	Christofyllakis, K., Dilbaz, Z. G., Denker, S., Ankermann, C., Kunte, A., Poeschel, V., Bewarder, M., Kaddu-Mulindwa, D., Stilgenbauer, S., Thurner, L., Na, I.-K., Bittenbring, J.-T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431504/ http://dx.doi.org/10.1097/01.HS9.0000851248.55582.e5

Ejemplares similares

Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP
por: Bewarder, Moritz, et al.
Publicado: (2023)

Vitamin D Enhances Immune Effector Pathways of NK Cells Thus Providing a Mechanistic Explanation for the Increased Effectiveness of Therapeutic Monoclonal Antibodies
por: Christofyllakis, Konstantinos, et al.
Publicado: (2023)

Current Treatment Options in CLL
por: Bewarder, Moritz, et al.
Publicado: (2021)

Management of Extranodal Marginal Zone Lymphoma: Present and Upcoming Perspectives
por: Kaddu-Mulindwa, Dominic, et al.
Publicado: (2022)

Advances in Lymphoma Molecular Diagnostics
por: Kos, Igor Age, et al.
Publicado: (2021)

Adjuvant Therapy of High-Risk (Stages IIC–IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis
por: Christofyllakis, Konstantinos, et al.
Publicado: (2021)

PB2104: SOLUBLE B-CELL MATURATION ANTIGEN AS A MONITORING MARKER FOR MULTIPLE MYELOMA
por: Wiedemann, Ádám, et al.
Publicado: (2023)

Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potential
por: Bewarder, Moritz, et al.
Publicado: (2020)

The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells
por: Bewarder, Moritz, et al.
Publicado: (2021)

Integration of the B-Cell Receptor Antigen Neurabin-I/SAMD14 Into an Antibody Format as New Therapeutic Approach for the Treatment of Primary CNS Lymphoma
por: Bewarder, Moritz, et al.
Publicado: (2020)

Increased B‐cell activity with consumption of activated monocytes in severe COVID‐19 patients
por: Kos, Igor, et al.
Publicado: (2021)

IgG seroprevalence of COVID‐19 among people living with HIV or at high risk of HIV in south‐west Germany: A seroprevalence study
por: Kaddu‐Mulindwa, Dominic, et al.
Publicado: (2021)

PB2301: OPTIMAL DOSE INTENSITY OF R-CHOP FOR PATIENTS WITH DLBCL AGED 80 YEARS OR OLDER: IS THE R-MINICHOP A GOLD STANDARD?
por: Nukariya, Hironao, et al.
Publicado: (2023)

Protection strategy against outbreak of COVID-19 at a tertiary hematology-oncology: strengths and pitfalls
por: Kaddu-Mulindwa, Dominic, et al.
Publicado: (2021)

Ars2‐containing bispecific, Fab‐ and IgG1‐format BAR‐bodies to target DLBCL cells
por: Kiefer, Maximilian, et al.
Publicado: (2022)

Killer immunoglobulin-like receptor 2DS5 is associated with recovery from coronavirus disease 2019
por: Lesan, Vadim, et al.
Publicado: (2021)

PB2335: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHOP (O-CHOP) VERSUS R-CHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (OLYMPIA-3)
por: Tessoulin, Benoit, et al.
Publicado: (2023)

Prolonged Course of COVID-19-Associated Pneumonia in a B-Cell Depleted Patient After Rituximab
por: Kos, Igor, et al.
Publicado: (2020)

PB2325: VALIDATION OF THE TRAIL SCORE TO PREDICT TOXICITY IN PATIENTS WITH DLBCL RECEIVING R-CHOP-LIKE THERAPY
por: Caballero, Juan Carlos, et al.
Publicado: (2023)

FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials
por: Kaddu-Mulindwa, Dominic, et al.
Publicado: (2021)

PB2134: THE ROLE OF ADDITIONAL CARBOGEN GAS MIXTURE AND NICOTINAMIDE ON R-CHOP CHEMOTHERAPY IN DLBCL PATIENTS WITH TUMOR HYPOXIA
por: Rizky, D., et al.
Publicado: (2022)

PB2128: CELL OF ORIGIN ACCORDING TO HANS LOGARITHM IS AN INDEPENDENT RISK FACTOR FOR DLBCL PATIENTS TREATED WITH R-CHOP: A REAL WORLD MOROCCAN EXPERIENCE
por: Mahtat, E. M., et al.
Publicado: (2022)

PB2113: FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA
por: Vitolo, U., et al.
Publicado: (2022)

PB2084: FIRST-LINE TREATMENT IN ADVANCED STAGE FOLICULAR LYMPHOMA: A SINGLE-CENTER EXPERIENCE WITH R-CHOP VS BENDAMUSTINE-RITUXIMAB.
por: Mompel, O., et al.
Publicado: (2022)

PB2362: THE EFFECT OF BODY MASS INDEX (BMI) ON THE PROGNOSIS OF DLBCL PATIENTS TREATED WITH R-CHOP: A REAL WORLD MOROCCAN EXPERIENCE
por: el Filali, Imane Ait, et al.
Publicado: (2023)

Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial
por: Held, Gerhard, et al.
Publicado: (2023)

PB2170: HIGH EXPRESSION OF AP2M1 CORRELATES WITH WORSE PROGNOSIS BY REGULATING IMMUNE MICROENVIRONMENT AND DRUG RESPONSE TO R-CHOP IN DLBCL
por: Liu, X.-D., et al.
Publicado: (2022)

PB2110: PHARMACOKINETICS AND PHARMACODYNAMICS IN FIRST-MIND: A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY OF TAFASITAMAB ± LENALIDOMIDE + R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA
por: Belada, D., et al.
Publicado: (2022)

PB2310: CHIDAMIDE WITH AZACITIDINE AND CHOP TREATMENT FOR PATIENTS WITH NEWLY DIAGNOSED PERIPHERAL T-CELL LYMPHOMA:INTERIM ANALYSIS OF A PROSPECTIVE,SINGLE CENTER,SINGLE-ARM, PHASE 2 TRIAL
por: Xiao, Chunyan, et al.
Publicado: (2023)

Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study
por: Thurner, Lorenz, et al.
Publicado: (2023)

PB2307: PHARMACOKINETICS, EFFICACY AND SAFETY OF SUBCUTANEOUS VERSUS INTRAVENOUS RITUXIMAB COMBINED WITH CHOP IN CHINESE PATIENTS WITH UNTREATED CD20-POSITIVE DIFFUSE LARGE B CELL LYMPHOMA: A RANDOMIZED TRIAL
por: Gao, Yan, et al.
Publicado: (2023)

PB2175: TRYPAN BLUE AND FLOW CYTOMETRY CELL VIABILITY TESTING OF PACKED OR DILUTED CRYOPRESERVED AT -80ºC HEMATOPOIETIC STEM CELLS SHOW SIMILAR RESULTS
por: Tonev, I., et al.
Publicado: (2022)

PROJECT ADMINISTRATION AGREEMENT KN2104/TE
por: THE EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH, CERN, et al.
Publicado: (2012)

PROJECT ADMINISTRATION AGREEMENT KN2104/TE
por: THE EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH, CERN, et al.
Publicado: (2012)

PB2609: 14 YEARS OF EXPERIENCE WITH THROMBOPOIETIN RECEPTOR AGONISTS IN A SINGLE CENTER
por: Garcia-Pallarols, Francesc, et al.
Publicado: (2023)

PB1773: MYBLOCK: A MYELOID BLOOD CANCER INITIATIVE
por: Cairns, L., et al.
Publicado: (2022)

Fewer neurocognitive deficits and less brain atrophy by third ventricle measurement in PLWH treated with modern ART: A prospective analysis
por: Kaddu-Mulindwa, Dominic, et al.
Publicado: (2022)

PB2303: THROMBOCYTOPENIA IN COVID-19 PATIENTS ON ECMO SUPPORT
por: Jones, C., et al.
Publicado: (2022)

PB1885: THE ROLE OF PET CT IN HAIRY CELL LEUKEMIA
por: itchaki, G., et al.
Publicado: (2022)

PB1931: HEMATOLOGICAL COMPLICATIONS OF COVID IMMUNIZATION-CASE SERIES
por: Aribandi, A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nvo4ui8kfqaknkvgmp9bm2oa5i